

WHAT IS CLAIMED IS:

1. A plastic-adsorbing compound having anti-KS and anti-HIV pharmaceutical activity which comprises at least one biologically active compound isolated from a biologically active fraction of APL-HCG.

2. A plastic-adsorbing compound of claim 1, wherein said at least one biologically active compound has a molecular weight of less than about 14,000 Dalton.

3. The plastic-adsorbing compound of claim 1, wherein said at least one biologically active compound has an amino acid sequence selected from the group consisting of :

Ser-Lys-Glu-Pro-Leu-Arg-Pro-Arg-Glu-Arg-Pro-Ile-Asn*-
Ala-Thr-Leu-Ala-Val-Glu-Lys SEQ ID NO:1;
and

Ala-Pro-Asp-Val-Gln-Asp-Lys-Phe-Thr-Arg-Gln-Ile-Met-
Ala-Thr SEQ ID NO:2;

and biologically active derivatives and fragments thereof.

4. The plastic-adsorbing compound of claim 3, wherein said derivatives contain one or more D-amino acids or non-natural amino acids.

5. A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and/or HIV which comprises a therapeutically effective amount of at least one compound of claim 1, in association with a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and/or HIV which comprises a therapeutically effective amount of at least one compound of claim 3, in association with a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 5, which is formulated as a controlled release formulation.

8. A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and/or HIV expression in AIDS patients, which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

9. A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and/or HIV expression in AIDS patients, which comprises administering to said patient a therapeutically effective amount of a pharmaceutical composition of claim 5.

10. A method to purify the compound of claim 1, which comprises the steps of:

- a) subjecting a biologically active fraction of APL-HCG or urinary extract containing said compound or protein to a polypropylene plastic support for a time sufficient for adsorption of said compound or protein to occur; and
- b) washing the support and releasing the adsorbed compound or protein therefrom.

11. A method of evaluating biological anti-KS and anti-HIV activity of a polypropylene-adsorbing compound of claim 1, which comprises measuring AP1 gene activity.

12. The method of claim 11, wherein measuring of said AP1 gene activity is effected by measuring binding to DNA response element.